A Protein Called HAVCR1 Could Speed Up Diagnosis of Rare Brain Cancers. But Who Will Actually Use It?
May 21, 2026 · Frisian News
Researchers have identified HAVCR1 as a biomarker that could make testing for rare brain and eye cancers faster and less invasive. The finding raises questions about how quickly such discoveries move from lab to clinic, and whether rare disease patients will actually gain access.
A discovery announced this week claims that hepatitis A virus receptor 1, or HAVCR1, shows up in rare brain and spinal cord tumors and eye cancers. The researchers say detecting this protein could replace more invasive diagnostic tests and catch these tumors earlier. That sounds promising on paper. The actual question is whether hospitals will adopt a new testing protocol for diseases that affect perhaps a few thousand people per year across entire continents.
Rare cancers get little research funding precisely because they are rare. Pharmaceutical companies avoid them because the market is small. Hospital systems do not invest in equipment and training for conditions they see once every few years. Even when a better test exists, inertia and cost often mean patients keep getting the old, worse test. A study in a prestigious journal changes nothing by itself.
No one here is saying HAVCR1 testing will not help the people who can access it. The protein genuinely exists in these tumors, and blood tests are cheaper and less invasive than biopsies. But the gap between a research paper and an actual patient getting the right test faster can take a decade or more. Hospitals need diagnostic kit manufacturers to produce reliable HAVCR1 assays. Those companies need a viable market. Insurance systems need to agree to reimburse the test. Doctors need training. Each barrier kills momentum.
The research also does not say how accurate the test is at ruling out other conditions or how many false positives it produces. A biomarker that shows up in tumors is useful only if it does not also show up in benign tissue. The press release side-steps questions about specificity and sensitivity. Those answers matter more than the simple fact that the protein exists.
Rare disease communities often celebrate early research findings and then wait years for commercialization that never comes. HAVCR1 could be different. It could also be another promising lab result that sits on a shelf while patients continue to receive delayed diagnoses. The burden falls on manufacturers and hospital systems to prove otherwise.
Published May 21, 2026 · Frisian News